SecBot SecBot
COURT-RULING ·Filed Jul 15, 2026

CORT

CORCEPT THERAPEUTICS INC
BULLISH
Impact 4/10
Horizonweeks Processed4mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight ▲ Bullish

The ruling is a modest positive for Corcept as it gains limited CEO-level testimony that could support its causation defense, but the core antitrust case (Teva v. Corcept over mifepristone for Cushing's syndrome) remains active. Monitor the Francis deposition (due by Aug 5, 2026) and any subsequent summary judgment motions for material developments.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$89.72
T+0 close · Jul 16, 2026 · via day close
Latest settled
+35.08%
T+60 · $121.19
Vs SPY
+31.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $89.72entry
  2. T+1 · 4mo ago +0.89%α +1.88% · $90.52
  3. T+5 · 4mo ago +7.74%α +9.41% · $96.66
  4. T+20 · 3mo ago +23.17%α +19.55% · $110.51
  5. T+60 · 6w ago +35.08%α +31.37% · $121.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corcept won a limited discovery ruling in its antitrust defense against Teva Pharmaceuticals. The court granted Corcept permission to depose Teva's CEO Richard Francis for up to 2 hours regarding his critique of Teva's mifepristone strategy, but denied Corcept's broader requests to depose him on pricing/distribution and to collect his custodial documents. This is a modest procedural victory for Corcept, it gains some ammunition to argue Teva's generic mifepristone failed due to Teva's own choices, not Corcept's conduct, but the substance of the underlying antitrust case remains unresolved.

Court Ruling Details

Ruling Date
Jul 15, 2026
Court
United States District Court for the Northern District of California
Court Level
District
Judge
Virginia K. DeMarchi
Case Type
antitrust
Ruling Type
discovery
Outcome
PARTIAL: mixed ruling, some claims won/lost
Precedent Risk
LOW

Key Facts

  • Court granted Corcept permission to depose Teva CEO Richard Francis for up to 2 hours on his critique of Teva's mifepristone strategy and possible solutions
  • Court denied Corcept's requests to depose Francis on pricing, distribution strategy, and to collect his custodial documents
  • The ruling does not resolve the underlying antitrust claims; it is a discovery-level procedural order
  • No damages were awarded, no injunction issued, and the case continues

Financial Impact

No financial impact quantified in the ruling; pure procedural discovery order

Risk Factors

  • The underlying antitrust case remains unresolved, a loss could still carry financial or behavioral remedies
  • Limited scope of deposition may not yield the admissions Corcept needs
  • Appeal or escalation by Teva on procedural grounds is possible

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-10e56aaee5-CORT

Track record

36 reports on CORT

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
  3. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
  5. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
  7. Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
  8. Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
  9. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
  10. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 7h 44m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Jul 16, 2026